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Abstract The use of β-agonists as growth promoters in
cattle breeding is forbidden in many countries for reasons
of fair trade and consumer protection. In recent years the
use of liquid chromatography (LC) tandem mass spectrom-
etry (MS/MS) has been shown to be the method of choice
for the control of β-agonists. In this study an LC-MS/MS
multiresidue analysis method is presented for trace analysis
of 22 β-agonists. A truly generic concept has been designed
based on mixed-mode solid-phase extraction and positive
electrospray ionisation LC-MS/MS operated in the multiple
reaction monitoring mode. This method allows application
to a wide variety of sample matrices such as urine, feed and
hair, following minor modifications to the analysis proce-
dure only. The method features fit-for-purpose sensitivity in
urine as shown by CCα and CCβ values of less than 0.2
and less than 0.5 μg/l respectively, for all β-agonists
studied (terbutaline and reproterol, less than 0.3 and less
than 1.0 respectively). Similar but semiquantitative appli-
cation to feed and hair showed CCβ values of less than
10.0 and less than 5.0 μg/kg, respectively. A further
simplification and improvement is demonstrated using
Ultra Performance LC (UPLC™) and fast-switching MS/
MS. The successful validation of this method following the
latest EU requirements and its application to real samples
demonstrate that a new versatile tool has been achieved for
veterinary control of β-agonists.
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Introduction
The use of growth promoters for fattening purposes in cattle
has been banned in the European Union since 1988 [1].
Residue analysis on target compounds is carried out by
several control laboratories in order to protect the consumer,
guarantee fair trade and enforce the ban [2]. Apart from
steroids having androgenic, estrogenic or progestagenic
activity, thyreostatics and β-agonists are banned as well
[3, 4]. Especially in the case of β-agonists, health pro-
tection is an issue: several clinical cases of acute food
intoxication following the consumption of liver or meat are
documented, one of the clinical symptoms being heart
disorders which can be fatal [5, 6]. According to a feed
producers’ magazine more than 300 people at a time were
poisoned recently in China following the consumption of
pork produced by pigs fed with a β-agonist as a feed
additive [7]. Obviously there is a need for a multi β-agonist
residue analysis method which is applicable to a wide
variety of sample matrices such as feed, urine, hair and
tissue. Radio and enzyme immunoassay screening tools
were developed in the past and are still being used in many
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countries for the control of β-agonists [8, 9]. A more
sophisticated immunological approach based on a surface
plasmon resonance (SPR) biosensor was presented by
Traynor et al. [10]. However, both suffer from the limited
degree of cross-reactivity of the antibodies used, covering
a maximum of eight to 13 β-agonists only. Many more
β-agonists are known from human medicine and more-
over “black-market” chemists are highly active in design-
ing structure analogues of β-agonists which cannot be
traced by classic routine methods [11–13]. A more generic
functional test based on the detection of smooth muscle
relaxation of isolated trachea strips from guinea pigs might
be considered but is rather laborious, relatively slow and
not very sensitive [14]. Meenagh et al. [15] developed a
competition binding assay for β-agonists based on solubi-
lised human β2-adrenoreceptors isolated from transfected
Chinese hamster ovary cells and the tritiated antagonist
dihydroalprenolol as a radioactivity label. Such an assay is
able to detect novel derivatives which exhibit the same
pharmacological action as β-agonists but have modified
chemical structures. Unfortunately this receptor binding assay
is not sensitive enough for the low levels encountered in urine
and tissue samples. As an alternative gas chromatography–
mass spectrometry (MS) and liquid chromatography (LC)
tandem MS (MS/MS) methods are being used to monitor
selected ions or multiple reaction monitoring (MRM) MS/MS
transitions [16–22]. Huang et al. [23] even omitted the LC
separation step by incorporating the selectivities of a
polymeric monolith microextraction column and quadrupole
time-of-flight MS in the analysis of three β-agonists in pork.
The LC-MS/MS methods developed so far include either a
smaller number of β-agonists [16–21] than the SPR biosensor
assay [10], and/or show a limited scope of either calf or
human urine and/or tissue applicability. In this study we
developed a multimatrix multianalyte LC-MS/MS method for
the residue analysis of β-agonists in feed, in bovine and
porcine urine, and in hair. The method described comprises
22 β-agonists and three, isotope-labelled internal standards
and was validated using the latest EU requirements [24].
According to these requirements the CCβ and CCα values
must be established amongst other parameters. The detection
capability CCβ is defined as “the smallest content of the
substance that may be detected, identified and/or quantified
in a sample with an error probability of β. In the case of
substances for which no permitted limit has been established,
the detection capability is the lowest concentration at which a
method is able to detect truly contaminated samples with a
statistical certainty of 1 - β” [24]. The decision limit CCα is
defined as “the limit at and above which it can be concluded
with an error probability of α that a sample is non-compliant”
[24], or in other words, at which level are you sure that the
sample really contains the substance.
Recently, Churchwell et al. [25] showed increased LC-
MS/MS performance for a standard solution containing
nine β-agonists using Ultra Performance LC (UPLC™) and
a fast-switching triple-quadrupole MS/MS instrument.
Following purchase of that instrument, we managed to
further simplify and speed up our multi method and to
present data on the applicability of Ultra Performance LC-
MS/MS in real sample matrices.
Experimental
Chemicals
The chemicals and solutions used were of analytical-
reagent grade. Water was purified using a Milli-Q system
from Millipore (Bedford, MA, USA). Brombuterol, clency-
clohexerol, clenpenterol and clenproperol were obtained
from the Community Reference Laboratory BVL (Berlin,
Germany). Clenbuterol chloride, fenoterol bromide, proca-
terol chloride, isoxsuprine and salbutamol sulphate were
obtained from Sigma (St. Louis, MO, USA). Carbuterol
chloride was obtained from Warner-Lambert (Belgium).
Mabuterol chloride and mapenterol chloride were from
Rephartox (Lelystad, The Netherlands). Terbutaline sul-
phate was obtained from Bufa (Uitgeest, The Netherlands).
Cimbuterol, cimaterol, ractopamine and tulobuterol were a
gift from F. André (ENVN, Nantes, France). Salmeterol
was a gift from A. Bast (Free University, Amsterdam, The
Netherlands). Clenhexyl chloridewas a gift fromD. Courtheyn
(FAVV, Ghent, Belgium). Zilpaterol was a gift from E.
van der Vlis (TNO, Zeist, The Netherlands). Reproterol
chloride was from laboratory stock. The designer β-agonist
clenbuterol-R was obtained from a purified feed extract [12].
The isotope-labelled internal standards clenbuterol-d6 and
salbutamol-d6 were custom-synthesised at Wageningen
University and Research Centre (Wageningen, The Nether-
lands); ractopamine-d5 chloride was obtained from the
Community Reference Laboratory BVL. Stock solutions
of the β-agonists were prepared in methanol at 1 mg/ml.
β-Glucuronidase/arylsulphatase (from suc Helix pomatia)
was from Merck (Darmstadt, Germany). Bondelut Certify
mixed-mode solid-phase extraction (SPE) columns (300 mg)
were from Varian (Harbor City, CA, USA).
Sample materials
In the validation studies 25 independent blank bovine and
porcine urine samples and 20 blank bovine hair samples
from different animals were used, as well as 20 blank feed
samples. Incurred bovine urine and hair samples were
obtained from a veterinary control programme.
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Sample preparation
Urine
Urine sample, blanks and controls (2 ml) were spiked with
the internal standard mixture at 2 ng/ml. The control urine
samples were prepared by spiking blank urine samples with
the β-agonist mixture at 0.125, 0.25, 0.50, 1.0 and
2.0 ng/ml, except for clenbuterol, which was spiked at two-
fold lower levels. Following the addition of 3 ml of 0.25 M
sodium acetate buffer pH 4.8 and 10 μl of β-glucuronidase/
arylsulphatase, enzymatic deconjugation was carried out in
a water bath at 55 °C for 2 h. Next, the hydrolysed sample
was subjected to SPE on a mixed-mode column, previously
conditioned by methanol and sodium acetate buffer. The
vacuum-dried SPE column was washed subsequently with
1 ml of 1 M acetic acid, 6 ml of methanol and 2 ml of
acetone/chloroform (1:1). Finally the contents of the dried
SPE column were eluted with 7.5 ml of 3% ammonia in
ethyl acetate and the eluate was evaporated to dryness under
a stream of nitrogen gas at 40 °C. The residue obtained was
redissolved in 50 μl of acetonitrile and following the
addition of 250 μl of 0.24% formic acid 50 μl was injected
into the LC-MS/MS system.
Feed
Two 2.5-g portions of homogenised feed sample, blanks
and controls were spiked with the internal standards at
24 ng/g. In addition, one of these portions was spiked with
the β-agonist standard mixture at 10 ng/g (clenbuterol at
5 ng/g). Following a 15 min equilibration, to both portions
25 ml of 0.2 M phosphoric acid/methanol (1:1) was added.
Next, the mixtures were shaken for 30 min in a head-over-
head apparatus and centrifuged for 10 min at 2,800 g.
Finally 1.6 ml of the supernatants was transferred to
individual test tubes, 5 ml of 0.25 M sodium acetate buffer
pH 4.8 was added and the extracts were further subjected to
SPE as described for urine samples.
Hair
Two 500-mg portions of hair sample previously cut to less
than 2 cm, blanks and controls were spiked with the
internal standard ractopamine-d5 at 10 ng/g. In addition,
one of these portions was spiked with the β-agonist
standard mixture at 5 ng/g. The control hair samples were
prepared by spiking blank hair with the β-agonist standard
mixture at 0, 2.5, 5.0, 10, 20 and 50 ng/g. Following the
addition of 4 ml NaOH (1.0 M) solution, digestion was
carried out in a water bath at 65 °C for 2 h. Next, 3.5 ml of
HCl (1.0 M) and 5 ml of 0.25 M sodium acetate buffer
pH 4.8 were added and the test tubes were centrifuged for
10 min at 2,000 g. The supernatants were transferred to a
clean test tube, adjusted to pH 4.8 if necessary, and
centrifuged again for 10 min at 2,000 g. The supernatants
thus obtained were further subjected to SPE as described
for urine samples.
Liquid chromatography–mass spectrometry
Conventional LC-MS/MS
The LC-MS/MS system consisted of a Waters (Milford,
MA, USA) model Alliance 2690 LC system equipped with
a Micromass (Manchester, UK) model Quattro Ultima
triple-quadrupole mass spectrometer. The mass spectrome-
ter was operated in the positive electrospray ionisation
(ESI) mode at a capillary voltage of 2.7 kV, a desolvation
temperature of 300 °C, a source temperature of 120 °C and
a cone voltage of 35 V. The desolvation gas was nitrogen
and the collision-induced dissociation (CID) gas was argon.
For each analyte, the most abundant MRM transition was
acquired using the conditions given in Table 1. Because of
Table 1 Positive ion tandem mass spectrometry (MS/MS) conditions
for the multiple reaction monitoring (MRM) acquisition of β-agonists
Component Precursor ion
mass (m/z)
Product ion
mass (m/z)
Collision
energy (eV)
Cimaterol 220.1 160.1 15
Terbutaline 226.1 107.0 25
Cimbuterol 234.2 160.1 15
Salbutamol 240.2 148.1 20
Salbutamol-d6 246.2 148.1 20
Clenproperol 263.1 203.0 20
Clenbuterol 277.1 203.0 15
Clenbuterol-d6 283.1 204.0 15
Clenbuterol-R 471.2 415.1 20
Clenpenterol 291.1 203.0 17
Mabuterol 311.1 237.0 15
Mapenterol 325.1 237.0 15
Brombuterol 365.0 290.9 20
Zilpaterol 262.2 185.1 22
Carbuterol 268.2 134.1 25
Procaterol 291.2 231.1 20
Fenoterol 304.2 135.1 20
Reproterol 390.2 221.2 22
Tulobuterol 228.1 154.0 15
Isoxsuprine 302.2 150.1 20
Ractopamine 302.2 164.1 15
Ractopamine-d5 307.2 167.1 17
Clenhexyl 303.1 203.0 20
Clencyclohexerol 319.1 203.0 20
Salmeterol 416.3 232.2 20
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the limitation in the number of concurrent MRM transitions
with this instrument and because of the coelution tendency
of β-agonists in general, two separate injections from each
sample extract had to be performed in order to cover all 22
analytes and three internal standards. The analytical column
was a 150 mm×3.5-mm internal diameter 5-μm C18
Alltima (Alltech, Breda, The Netherlands) column, kept in
a column oven at 30 °C. The two mobile phases used
consisted of 100:0.2 water/formic acid (solvent A) and
100:0.2 acetonitrile/formic acid (solvent B) and the flow
rate was 0.4 ml/min. Following a 5-min isocratic period at
0% solvent B, a linear gradient was started towards 100%
solvent B at 20 min, and was kept at that composition until
20.5 min. The liquid chromatograph was connected to the
ESI MS/MS instrument using a 1:2 flow split.
The concentrations of β-agonists in urine samples were
calculated using the isotope dilution method and a linear
calibration graph was constructed from peak areas relative
to that of the internal standard obtained with blank and
spiked control samples prepared in urine (matrix-matched
standards, MMS). The response of the clenbuterol-d6
internal standard was used, except for the concentrations
of salbutamol and ractopamine, which were calculated
using the internal standards salbutamol-d6 and ractopamine-
d5, respectively. The concentrations of β-agonists in feed
samples were estimated using the isotope dilution method
and standard addition of 10 ng/g of each β-agonist
(clenbuterol at 5 ng/g) to each individual sample. The
concentrations of β-agonists in hair samples were estimated
using the isotope dilution method and standard addition of
5 ng/g of each β-agonist to each individual sample.
Ultra performance LC-MS/MS
The Ultra Performance LC-MS/MS system consisted of a
Waters model Acquity UPLC™ system equipped with a
Quattro Premier XE triple quadrupole mass spectrometer.
The mass spectrometer was operated in the positive ESI
mode at a capillary voltage of 2.0 kV, a desolvation
temperature of 350 °C, a source temperature of 120 °C
and a cone voltage of 20 V. The desolvation gas was
nitrogen and the CID gas was argon. The injection volume
was 40 μl and the chromatographic separation was
performed at 40 °C using an Acquity (Waters) BEH-C18
column (100 mm×2.1-mm internal diameter,1.7-μm parti-
cle size). The two mobile phases used consisted of 100:0.1
water/formic acid (solvent A) and 100:0.1 acetonitrile/
formic acid (solvent B) and the flow rate was 0.4 ml/min.
Following a 1-min isocratic period at 0% solvent B, a linear
gradient was started towards 35% solvent B at 8.0 min
(or 9.5 min in the case shown in Fig. 4) and 100% solvent B
at 8.5 min (or 9.8 min in the case shown in Fig. 4), and
was kept at that composition until 12.8 min. The liquid
chromatograph was connected to the ESI MS/MS instru-
ment without a flow split.
Quality assurance and validation
In all cases, standards, reagent blanks, matrix blanks and
spiked matrix control samples were analysed in the same
series. Run acceptance criteria for system stability, mini-
mum sensitivity, recovery of internal standards, recovery of
the standard addition or the linearity of the matrix-matched
control standards (where applicable) must be fulfilled for
each series. Accuracy results from the urine samples spiked
with 0.25 ng/ml clenbuterol and 0.5 ng/ml clenproperol and
salbutamol were plotted on a long-term quality control
chart. The validation study for the quantitative screening of
β-agonists in urine was carried out at three concentration
levels by the analysis of bovine and porcine urine samples
spiked with 1.0, 1.5 and 2.0 ng/ml of each β-agonist,
except for clenbuterol, which was spiked at twofold lower
levels. To each urine sample 2.0 ng/ml of the internal
standard mixture was added, and six replicates of each
sample were analysed on three different days. From the data
thus obtained, within-day repeatability, within-laboratory
reproducibility and accuracy were calculated. By doing so,
we included robustness data in the reproducibility results.
Furthermore it should be underlined that the ruggedness
was monitored in each individual urine analysis by
monitoring the signal intensity of the deuterated internal
standards. The recovery of the overall sample preparation
procedure was determined on two different days by the
analysis of bovine and porcine urine samples spiked at
1.0 ng/ml just before the sample preparation (clenbuterol at
0.5 ng/ml) and addition of the internal standard just before
injection into the LC-MS/MS system, i.e. internal standard
correction for injection volume and ion suppression only.
The linearity was determined for a limited concentration
range since the analytes of interest are banned substances
for which no safe maximum residue limits have been
established. To this end, urine samples spiked at 0.0, 0.125,
0.25, 0.50, 1.0 and 2.0 ng/ml, except for clenbuterol, which
was spiked at twofold lower levels, were analysed on three
different days.
The validation study for the qualitative screening of β-
agonists in feed was carried out by the analysis of 20
different feed samples with and without adding each β-
agonist at a level of 10 μg/kg (except for clenbuterol, which
was added at a level of 5 μg/kg). From the data thus
obtained, CCβ and the specificity were determined.
Because the analysis of β-agonists in feed is very similar
to the analysis of β-agonists in urine, it was not necessary
to determine the robustness.
The validation study for the qualitative confirmation of
β-agonists in hair was carried out by the analysis of 20
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different bovine (calf) hair samples with and without adding
each β-agonist at a level of 5.0 μg/kg. To each hair sample,
10 μg/kg of the internal standard mixture was added, and
the total set of samples was analysed on three different
days. From the data thus obtained, CCα, CCβ and the
specificity were determined. Robustness was determined by
analysing one hair sample with the addition of each β-
agonist and preparing this sample in 18-fold with minor
changes in the sample preparation. The linearity was
determined by the analysis of hair samples spiked at 0.0,
2.5, 5.0, 10, 20 and 50 μg/kg, which were analysed on four
different days.
Results and discussion
General considerations
The molecular structures of the β-agonists studied include
aniline and phenol derivatives and more complex structures
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Fig. 1 Structures of the β-
agonists studied: 1 clenbuterol,
2 clenproperol, 3 clenbuterol-R
[12], 4 clenpenterol, 5 brombu-
terol, 6 clencyclohexerol, 7
mapenterol, 8 clenhexyl, 9
mabuterol, 10 salbutamol, 11
cimaterol, 12 cimbuterol, 13
carbuterol, 14 terbutaline, 15
tulobuterol, 16 fenoterol, 17
procaterol, 18 ractopamine, 19
isoxsuprine, 20 zilpaterol, 21
reproterol, 22 salmeterol
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such as zilpaterol (Fig. 1). From these diverse structures it
is obvious that a single antibody can cover only a limited
number of them; possibly the development of a multiplex
immunological screening assay might become an alterna-
tive for LC-MS/MS multiresidue analysis in the future.
Classic triple-quadrupole MS/MS instruments are limited in
the number of concurrent MRM acquisitions. For the
present number of β-agonists this problem was solved by
performing two injections of each sample extract using the
same LC gradient but acquiring a different set of ion
transitions. The ion transitions given in Table 1 provide
adequate sensitivity and yield 2.5 identification points
according to [24]. A common fragmentation mechanism
for β-agonists is the loss of the alkyl group from the
secondary amine and the loss of water, yielding a stable
unsaturated primary amine ion and a neutral loss of m/z
116, 100, 88, 74 or 60 for the cyclohexerol, hexyl, pentyl,
butyl or propyl derivatives, respectively. Salbutamol and
salmeterol show a second loss of water and carbuterol
shows an additional loss of urea. In the case of reproterol
the substituent at the secondary amine keeps the positive
charge, while ractopamine and isoxsuprine show a neutral
loss consisting of the phenolic part of the molecule. Once a
specific β-agonist is suspected in this initial screening
procedure, the same method can be simply adjusted to a
confirmatory analysis method by replacing one or more of
the MRM transitions of apparently irrelevant β-agonist(s)
by a second or more MRM transitions for the suspected β-
agonist of interest. By doing so, one can easily achieve the
minimum number of 4.0 identification points for confirma-
tion of identity.
With the aim of a multianalyte multimatrix method, the
issue of matrix-matched standards (MMS) for validation
and quantification should be discussed. Urine is a homo-
geneous sample matrix and has a relatively constant
background composition. By selecting an appropriate set
of blank calf, bovine and porcine urine samples, one can
easily validate the method using MMS according to the EU
requirements [24] and it is justified to screen samples
quantitatively using an external multipoint MMS calibra-
tion curve. Still it should be kept in mind that ideally each
individual β-agonist would have its own isotope-labelled
analogue as an internal standard; the three internal stan-
dards in the present method are a compromise in that respect
and will not correct completely for recovery loss, ionisation
suppression or ionisation enhancement. For feed the
situation is quite different since the actual background
composition of a specific feed sample might differ
Table 2 Validation data for the quantitative screening of clenbuterol and 20 other β-agonists in urine by liquid chromatography (LC)–MS/MS
Analyte Clenbuterol 20 other β -agonists 
Spike level (µg/l) 0.5 1.0 0.75 1.0 1.5 2.0 
Repeatability (RSD,%) 6 4 3 5 −  24  3 − 26  3 − 16  
Within-lab reproducibility (RSD,%) 14 11 14 6 −  30 5 − 32 5 − 25 
Accuracy (%) 101 98 101 91 −  110 88 −  111 85 − 108 
Recovery (%) at 1.0 µg/l,  
0.5 µg/l for clenbuterol
76 54 − 85 
Linearity (r2, 0.15 − 2.0 µg/l,  
0.0625 − 1.0 µg/l for clenbuterol) 
≥0.990  
CCα (µg/l) 0.02 0.01 − 0.28
CCβ (µg/l)  0.04 0.09 − 0.99
Specificity Passed 
Ruggedness 
Validation parameters according to [24]; other conditions, see the text
RSD relative standard deviation
Passed 
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Fig. 2 Reconstructed multiple reaction monitoring (MRM) chromato-
grams for the screening of β-agonists in a control bovine urine sample
spiked at 1.0 μg/l and analysed by a two injections in a conventional
liquid chromatography (LC)–tandem mass spectrometry (MS/MS)
system and b one injection in an Ultra Performance LC (UPLC™)
MS/MS system represented by reconstructed MRM overlays. The
MRM ion transitions are given in Table 1. A salbutamol-d6, B
salbutamol, C cimbuterol, D terbutaline, E cimaterol, F brombuterol G
mapenterol, H mabuterol, I clenpenterol, J clenbuterol-d6; K clenbu-
terol, L clenproperol, M reproterol, N fenoterol, O procaterol, P
carbuterol, Q zilpaterol, R salmeterol, S clencyclohexerol, T clenhexyl,
U ractopamine, V isoxsuprine, W tulobuterol
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significantly from that of the feed samples used during
validation and from that of the MMS used for quantifica-
tion. Incomplete recovery and ionisation suppression are
likely to occur and only three internal standards are
available to indicate the potential occurrence of false-
compliant screening results. Therefore, we do not recom-
mend using the external multipoint MMS calibration
approach for feed. Alternatively we propose a one-point
standard addition procedure in which each sample under
investigation is split into two portions, one being analysed
straight away and the second being analysed following the
addition of the standard mixture of β-agonists. In this way,
each specific feed sample under investigation allows a
realistic check for false compliants due to incomplete
recovery and/or ionisation suppression. Moreover, a semi-
quantitative screening result is obtained. According to
Gratacós-Cubarsí et al. [26] hair samples should be also
considered as a complex matrix differing significantly in
composition. Again, because of the increased risk of
incomplete recovery and ionisation suppression and the
limited number of labelled internal standards we also prefer
the standard addition approach in the case of hair.
Validation studies
According to [24] the following performance characteristics
must be determined for a quantitative screening method:
detection capability CCβ, precision, selectivity/specificity
and ruggedness/stability. However, following an initial
multi β-agonists screening, confirmatory analysis of the
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Fig. 2 (continued)
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suspect sample will be required. In that case also the
decision limit CCα and the trueness/recovery validation
parameters must be assessed. At the beginning of the
validation study the specificity was checked by the analysis
of 23 urine samples from different bovines and porcines.
No interference on the β-agonist screening was found
owing to the highly specific MRM acquisition method and
the use of an appropriate deuterated internal standard. The
validation results for the quantitative analysis in urine are
summarised in Table 2. Despite the fact that only three
isotope-labelled internal standards were available the
accuracy is 85–111% in all cases. All β-agonists show
CCβ values less than 0.5 ng/ml, except terbutaline and
reproterol (less than 1.0 ng/ml), and all MMS calibration
curves show a correlation coefficient higher than 0.990.
From Table 2 it can be concluded that the method
developed shows relevant CCα and CCβ values, good
precision, accuracy and linearity, and fulfils the validation
criteria set for quantitative residue analysis methods [24].
Note that no quantitative validation data are presented for
the designer β-agonist clenbuterol-R because of the lack of
a sufficient amount of a high-purity standard. However, it
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Fig. 3 Reconstructed MRM chromatograms for the screening of β-
agonists in a control pig feed sample spiked at 10 μg/kg with the β-
agonist mixture from Fig. 2, and analysed by Ultra Performance LC
(UPLC™) MS/MS. The MRM ion transitions are given in Table 1.
For an explanation of the labelling, see the legend to Fig. 2
Anal Bioanal Chem (2008) 391:199–210 207
has been shown previously that a urine level of approxi-
mately 0.5 ng/ml (expressed as clenbuterol equivalents)
was sufficient for successful confirmation of identity [12].
The analysis procedure for the other matrices of interest
i.e. feed and hair is very similar (see “Experimental”).
Because of the use of the semiquantitative single-point
standard addition procedure advocated above, these appli-
cations were validated as qualitative screening (feed) and
qualitative confirmation (hair) methods. According to [24]
the following performance characteristics must be deter-
mined for a qualitative screening method: detection
capability CCβ, selectivity/specificity and ruggedness/sta-
bility. At the beginning of the validation studies for feed
and hair, the specificity was checked by the analysis of 20
feed samples and 20 bovine (calf) hair samples. No
interference on the β-agonist screening was found owing
to the highly specific MRM acquisition method. Interfer-
ences are inherently checked in each individual sample
owing to the standard addition procedure and the stability is
checked in each analysis series. The CCβ in feed was less
than 10 μg/kg, except for clenbuterol (less 5 μg/kg). When
β-agonists are illegally applied as growth promoters the
expected level of a β-agonist in feed will be in the milli-
gram per kilogram range, i.e. the sensitivity of the feed
method is also adequate for the detection of carryover and/
or residues in the feed supply following discontinued
application. The CCβ in hair was less than 5 μg/kg. β-
Agonists are expected to accumulate in hair owing to a
“multiple pool” model which includes (but is not restricted
to) passive diffusion from the bloodstream into the growing
cells at the base of the hair follicle [26]. For example in a
study by Gaillard et al. [27] the levels of clenbuterol found
in real samples ranged from 20 to 4,372 μg/kg; conse-
quently the CCβ values obtained in the hair method were
considered realistic and fit for purpose.
Ultra performance LC-MS/MS
A serious drawback of multiresidue analysis using a
conventional LC-MS/MS instrument is the restricted num-
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Fig. 4 Reconstructed MRM chromatograms for the confirmatory analysis of the β-agonist salmeterol in a a noncompliant urine sample and b a
noncompliant hair sample, analysed by Ultra Performance LC (UPLC™) MS/MS
Table 3 Confirmation data of a salmeterol suspect in urine and hair analysed by Ultra Performance LC-MS/MS
Matrix/analyte RRTexp
a RRTreq RRT passed Ion ratioexp
b Ion ratioreq Ion ratio passed
Urine salmeterol 1.68 1.63–1.72 y 0.71 0.56–0.84 y
Hair salmeterol 1.69 1.65–1.73 y 0.66 0.60–0.89 y
For conditions, see the text
RRT relative retention time
a RRT versus clenbuterol-d6 internal standard
b Area ratio of product ions from reconstructed MRM chromatograms
208 Anal Bioanal Chem (2008) 391:199–210
ber of MRM transitions which can be concurrently
acquired. Consequently in the procedure each sample must
be injected twice, thereby doubling the analysis time and no
additional MRM transitions can be added, either to extend
the scope to more β-agonists, or to allow for second MRM
transitions in order to comply with screening and confir-
matory analysis requirements in a single run. Recently an
Ultra Performance LC system (UPLC™) and a fast-
switching triple-quadrupole MS/MS instrument have been
installed and indeed many more MRM transitions can be
acquired now, allowing multi β-agonist screening by one
injection only, without compromising the sensitivity.
Moreover, the UPLC™ system provides a much faster LC
separation, thereby reducing the runtime to less than
15 min. Figure 2 shows a comparison of a 1 μg/l spiked
control bovine urine sample analysed by conventional LC-
MS/MS requiring two injections, and by Ultra Performance
LC-MS/MS in just one injection. Apart from the overall
increase in speed the chromatographic resolution and peak
shape improved considerably, yielding an improved signal-
to-noise ratio, thanks to the high-resolution column.
Figure 3 shows a 10 μg/kg spiked control pig feed sample
analysed by Ultra Performance LC-MS/MS. Even in this
highly complex sample matrix an excellent signal-to-noise
ratio is obtained for all β-agonists in a single injection and
at a fast runtime.
Applicability in veterinary control
The multianalyte multimatrix procedure developed has
been applied to calf, bovine and porcine urine, and to a
wide variety of dry and wet feed samples within the scope
of national control and monitoring programmes; more
recently the method has been applied to hair analysis as
well. So far this β-agonist screening method has been
shown to be extremely robust: the percentage of reanalysis
caused by noncompliance with the run-acceptance criteria
is lower than 5%. In general, findings of incurred samples
being noncompliant for one or more β-agonists are rare;
two examples are given here for residues of salmeterol. In
the screening, the samples were suspect by showing a clear
signal in the reconstructed MRM chromatogram at the
correct retention time. Next, the confirmation of identity
according to [24] was demonstrated by reanalysis of the
suspect urine and hair samples. In order to achieve this a
second MRM ion transition (m/z 416.4 > m/z 380.3) was
added to the MS/MS acquisition method. The precursor ion
and two product ions recorded in MRM mode yielded the
minimum requirement of four identification points. The
results are given in Table 3 and show that all identification
criteria were fulfilled, thus yielding noncompliant results
[24]. The concentrations in the incurred urine (Fig. 4a) and
hair (Fig. 4b) samples were 0.6 μg/l and approximately
4 μg/kg, respectively.
Conclusions
A truly multianalyte multimatrix robust LC-MS/MS residue
analysis concept has been developed and validated for β-
agonists in urine, feed and hair at relevant levels. The method
is suitable for both conventional LC-MS/MS screening as
well as the most recent Ultra Performance LC (UPLC™)
MS/MS instruments, the latter showing the benefit of having
screening results from a single injection, faster chromatog-
raphy, improved peak shape and signal-to-noise ratio, and
the possibility of additional ion transitions for other existing
or emerging β-agonists in veterinary control.
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